Antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3 and their uses

Patent metadata

Field	Value
Publication number	US-12173064-B2
Application number	US-202017090961-A
Country	US
Kind code	B2
Filing date	Nov 6, 2020
Priority date	Nov 3, 2015
Publication date	Dec 24, 2024
Grant date	Dec 24, 2024

Abstract

The present invention relates to antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.

First claim

What is claimed is:

1. A polynucleotide
(a) encoding the VH of SEQ ID NOs: 41, 42, 43 or 48 and the VL of SEQ ID NOs: 49, 50, 51, 52, 53, 54, 55 or 56, wherein the encoding VH and VL comprise SEQ ID NOs: 41 and 49, 41 and 50, 42 and 51, 42 and 52, 42 and 53, 43 and 49, 43 and 54, 43 and 50, 43 and 55, 43 and 56, 48 and 53, 48 and 52, 48 and 56; or
(b) comprising the polynucleotide sequences of SEQ ID NOs: 196 and 197.

2. A vector comprising the polynucleotide of claim 1 .

3. A host cell comprising the vector of claim 2 .

4. A method of producing an antagonistic antibody specifically binding PD-1 or an antigen-binding portion thereof, comprising culturing the host cell of claim 3 in conditions that the antibody of the antigen-binding portion thereof is expressed, and recovering the antibody or the antigen-binding portion thereof produced by the host cell.

5. A polynucleotide
(a) encoding the VH of SEQ ID NO: 64 and the VL of SEQ ID NO: 65; or
(b) comprising the polynucleotide sequences of SEQ ID NOs: 198 and 199.

6. A vector comprising the polynucleotide of claim 5 .

7. A host cell comprising the vector of claim 6 .

8. A method of producing an antagonistic antibody specifically binding PD-1 or an antigen-binding portion thereof, comprising culturing the host cell of claim 7 in conditions that the antibody or the antigen-binding portion thereof is expressed, and recovering the antibody or the antigen-binding portion thereof produced by the host cell.

9. A method of treating a cancer in a subject, comprising administering a therapeutically effective amount of-an isolated antibody or the antigen-binding portion thereof to the subject in need thereof for a time sufficient to treat the cancer wherein the isolated antibody or the antigen-binding portion thereof comprises an HCDR1, HCDR2, and HCDR3, and an LCDR1, LCDR2, and LCDR3 of SEQ ID NOs:
(a) 10, 13, 16, 20, 26 and 31, respectively;
(b) 10, 13, 16, 21, 26 and 32, respectively;
(c) 10, 14, 16, 22, 27 and 33, respectively;
(d) 10, 14, 16, 22, 26 and 34, respectively;
(e) 10, 14, 16, 23, 28 and 35, respectively;
(f) 10, 13, 17, 20, 26 and 31, respectively;
(g) 10, 13, 17, 20, 26 and 36, respectively;
(h) 10, 13, 17, 21, 26 and 32, respectively;
(i) 10, 13, 17, 21, 27 and 37, respectively;
(j) 10, 13, 17, 23, 26 and 32, respectively;
(k) 10, 14, 17, 23, 28 and 35, respectively;
(l) 10, 14, 17, 22, 26 and 34, respectively; or
(m) 10, 14, 17, 23, 26 and 32, respectively.

10. A method of treating a cancer in a subject, comprising administering a therapeutically effective amount of the isolated antibody or the antigen-binding portion thereof to the subject in need thereof for a time sufficient to treat the cancer wherein the isolated antibody or the antigen-binding fragment thereof comprises
(a) an HCDR1, HCDR2, and HCDR3, and an LCDR1, LCDR2, and LCDR3 of SEQ ID NOs: 66, 67, 68, 69, 70 and 71, respectively;
(b) a VH of SEQ ID NO: 64 and a VL of SEQ ID NO: 65; and/or
(c) a HC of SEQ ID NO: 74 and a LC of SEQ ID NO: 75.

11. The method of claim 9 , wherein the cancer is a solid tumor or a hematological malignancy.

12. The method of claim 11 , wherein the solid tumor is a melanoma, a lung cancer, a squamous non-small cell lung cancer (NSCLC), a non-squamous NSCLC, a colorectal cancer, a prostate cancer, a castration-resistant prostate cancer, a stomach cancer, an ovarian cancer, a gastric cancer, a liver cancer, a pancreatic cancer, a thyroid cancer, a squamous cell carcinoma of the head and neck, carcinomas of the esophagus or gastrointestinal tract, a breast cancer, a fallopian tube cancer, a brain cancer, an urethral cancer, a genitourinary cancer, an endometriosis, a cervical cancer or a metastatic lesion of the cancer.

13. The method of claim 11 , wherein the hematological malignancy is a lymphoma, a myeloma or a leukemia.

14. A method of enhancing an immune response in a subject, comprising administering a therapeutically effective amount of an antibody or the antigen-binding portion thereof to the subject in need thereof for a time sufficient to enhance the immune response wherein the antibody or the antigen-binding portion thereof comprises an HCDR1, HCDR2, and HCDR3, and an LCDR1, LCDR2, and LCDR3 of SEQ ID NOs:
(a) 10, 13, 16, 20, 26 and 31, respectively;
(b) 10, 13, 16, 21, 26 and 32, respectively;
(c) 10, 14, 16, 22, 27 and 33, respectively;
(d) 10, 14, 16, 22, 26 and 34, respectively;
(e) 10, 14, 16, 23, 28 and 35, respectively;
(f) 10, 13, 17, 20, 26 and 31, respectively;
(g) 10, 13, 17, 20, 26 and 36, respectively;
(h) 10, 13, 17, 21, 26 and 32, respectively;
(i) 10, 13, 17, 21, 27 and 37, respectively;
(j) 10, 13, 17, 23, 26 and 32, respectively;
(k) 10, 14, 17, 23, 28 and 35, respectively;
(l) 10, 14, 17, 22, 26 and 34, respectively; or
(m) 10, 14, 17, 23, 26 and 32, respectively.

15. The method of claim 14 , wherein the subject has a cancer or a viral infection.

16. The method of claim 9 , wherein the antibody or the antigen-binding portion thereof is administered in combination with a second therapeutic agent.

17. The method of claim 16 , wherein the second therapeutic agent is
a) a standard of care drug for treatment of the solid tumor or the hematological malignancy;
b) an agonist of a T cell activating molecule;
c) an agonist of CD86 (SEQ ID NO: 264), CD80 (SEQ ID NO: 265), CD28 (SEQ ID NO: 266), ICOS (SEQ ID NO: 267), ICOS ligand (SEQ ID NO: 268), TMIGD2 (SEQ ID NO: 269), CD40 (SEQ ID NO: 270), GITR (SEQ ID NO: 271), 4-1BB ligand (SEQ ID NO: 271), OX40 ligand (SEQ ID NO: 272), CD70 (SEQ ID NO: 274), CD40L (SEQ ID NO: 275), TNFRSF25 (SEQ ID NO: 264), LIGHT (SEQ ID NO: 277), GITR ligand (SEQ ID NO: 278), OX-40 (SEQ ID NO: 279), CD27 (SEQ ID NO: 280), CD137 (SEQ ID NO: 281), NKG2D (SEQ ID NO: 282), CD48 (SEQ ID NO: 283), CD226 (SEQ ID NO: 284), or MICA (SEQ ID NO: 285);
d) an inhibitor of a T cell inhibitory molecule;
e) an inhibitor of PD-1 (SEQ ID NO: 1), PD-L1 (SEQ ID NO: 5), PD-L2 (SEQ ID NO: 8), VISTA (SEQ ID NO: 286), BTNL2 (SEQ ID NO: 287), B7-H3 (SEQ ID NO: 288), B7-H4 (SEQ ID NO: 289), HVEM (SEQ ID NO: 290), HHLA2 (SEQ ID NO: 291), CTLA-4 (SEQ ID NO: 292), LAG-3 (SEQ ID NO: 293), TIM-3 (SEQ ID NO: 138), BTLA (SEQ ID NO: 294), CD160 (SEQ ID NO: 295), CEACAM-1 (SEQ ID NO: 296), LAIR1 (SEQ ID NO: 297), TGFβ (SEQ ID NO: 298), IL-10 (SEQ ID NO: 299), CD96 (SEQ ID NO: 300), TIGIT (SEQ ID NO: 301), NKG2A (SEQ ID NO: 302), CD112 (SEQ ID NO: 303), CD47 (SEQ ID NO: 304), SIRPA (SEQ ID NO: 305) or CD244 (SEQ ID NO: 306);
f) an antagonistic antibody specifically binding TIM-3;
g) an antagonistic antibody specifically binding TIM-3 comprising the VH and the VL of
i) SEQ ID NOs: 145 and 155, respectively;
ii) SEQ ID NOs: 146 and 156, respectively;
iii) SEQ ID NOs: 148 and 157, respectively;
iv) SEQ ID NOs: 147 and 155, respectively;
v) SEQ ID NOs: 149 and 158, respectively;
vi) SEQ ID NOs: 150 and 159, respectively;
vii) SEQ ID NOs:151 and 160, respectively;
viii) SEQ ID NOs: 152 and 161, respectively;
ix) SEQ ID NOs: 153 and 162, respectively;
x) SEQ ID NOs: 154 and 163, respectively; or
xi) SEQ ID NOs: 172 and 173, respectively;

h) a fibroblast growth factor receptor (FGFR) inhibitor;
i) a vaccine;
j) an agonistic antibody specifically binding GITR;
k) an agonistic antibody specifically binding OX40;
l) An agonistic antibody specifically binding OX40, comprising the VH and the VL of SEQ ID NOs: 309 and 310, respectively;
m) an agonistic antibody specifically binding OX40, comprising the VH and the VL of SEQ ID NOs: 311 and 312, respecti

Assignees

• Janssen Biotech Inc

Inventors

• Verona Raluca
• Powers Gordon
• Sabins Nina Chi
• Deangelis Nikki A
• Santulli-Marotto Sandra
• Wiehagen Karla R
• Wu Sheng-Jiun
• Ferrante Catherine
• Ubani Enrique Zudaire

Classifications

• C07K16/1145

  Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site · CPC title

• G01N33/5758

  involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K16/2818 Primary

  against CD28 or CD152 · CPC title